// App-Quantinova.ai

PB0061 : Standard dosing of Enoxaparin Versus unfractionated heparin in critically ill COVID19 patients: A Multicenter Cohort Study

Researchers

Presenter

  • A. Hafiz

Principal Investigators

  • G. Korayem

Medical Centers

  • King Abdulaziz University, Jeddah, Saudi Arabia

  • College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Ar Riyad, Saudi Arabia

  • Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Ar Riyad, Saudi Arabia

  • Pharmaceutical Care Services, King Khalid Hospital, Hail Health Cluster, Hail, Ha'il, Saudi Arabia

  • King Abdulaziz University, Jeddah, Saudi Arabia

Locations

  • Saudi Arabia

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Infectious Diseases (ID)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Heparin

  • Enoxaparin

  • Enoxaparin sodium

  • Heparin

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved